3-Methylcrotonyl-CoA carboxylase deficiency

WikiDoc Resources for 3-Methylcrotonyl-CoA carboxylase deficiency
Articles
Most recent articles on 3-Methylcrotonyl-CoA carboxylase deficiency Most cited articles on 3-Methylcrotonyl-CoA carboxylase deficiency Review articles on 3-Methylcrotonyl-CoA carboxylase deficiency Articles on 3-Methylcrotonyl-CoA carboxylase deficiency in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on 3-Methylcrotonyl-CoA carboxylase deficiency Images of 3-Methylcrotonyl-CoA carboxylase deficiency Photos of 3-Methylcrotonyl-CoA carboxylase deficiency Podcasts & MP3s on 3-Methylcrotonyl-CoA carboxylase deficiency Videos on 3-Methylcrotonyl-CoA carboxylase deficiency
Evidence Based Medicine
Cochrane Collaboration on 3-Methylcrotonyl-CoA carboxylase deficiency Bandolier on 3-Methylcrotonyl-CoA carboxylase deficiency TRIP on 3-Methylcrotonyl-CoA carboxylase deficiency
Clinical Trials
Ongoing Trials on 3-Methylcrotonyl-CoA carboxylase deficiency at Clinical Trials.gov Trial results on 3-Methylcrotonyl-CoA carboxylase deficiency Clinical Trials on 3-Methylcrotonyl-CoA carboxylase deficiency at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on 3-Methylcrotonyl-CoA carboxylase deficiency NICE Guidance on 3-Methylcrotonyl-CoA carboxylase deficiency NHS PRODIGY Guidance FDA on 3-Methylcrotonyl-CoA carboxylase deficiency CDC on 3-Methylcrotonyl-CoA carboxylase deficiency
Books
Books on 3-Methylcrotonyl-CoA carboxylase deficiency
News
3-Methylcrotonyl-CoA carboxylase deficiency in the news Be alerted to news on 3-Methylcrotonyl-CoA carboxylase deficiency News trends on 3-Methylcrotonyl-CoA carboxylase deficiency
Commentary
Blogs on 3-Methylcrotonyl-CoA carboxylase deficiency
Definitions
Definitions of 3-Methylcrotonyl-CoA carboxylase deficiency
Patient Resources / Community
Patient resources on 3-Methylcrotonyl-CoA carboxylase deficiency Discussion groups on 3-Methylcrotonyl-CoA carboxylase deficiency Patient Handouts on 3-Methylcrotonyl-CoA carboxylase deficiency Directions to Hospitals Treating 3-Methylcrotonyl-CoA carboxylase deficiency Risk calculators and risk factors for 3-Methylcrotonyl-CoA carboxylase deficiency
Healthcare Provider Resources
Symptoms of 3-Methylcrotonyl-CoA carboxylase deficiency Causes & Risk Factors for 3-Methylcrotonyl-CoA carboxylase deficiency Diagnostic studies for 3-Methylcrotonyl-CoA carboxylase deficiency Treatment of 3-Methylcrotonyl-CoA carboxylase deficiency
Continuing Medical Education (CME)
CME Programs on 3-Methylcrotonyl-CoA carboxylase deficiency
International
3-Methylcrotonyl-CoA carboxylase deficiency en Espanol 3-Methylcrotonyl-CoA carboxylase deficiency en Francais
Business
3-Methylcrotonyl-CoA carboxylase deficiency in the Marketplace Patents on 3-Methylcrotonyl-CoA carboxylase deficiency
Experimental / Informatics
List of terms related to 3-Methylcrotonyl-CoA carboxylase deficiency

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

3-Methylcrotonyl-CoA carboxylase deficiency (3MCC deficiency), also known as 3-Methylcrotonylglycinuria type 1 or BMCC deficiency is an inherited disorder in which the body is unable to process certain proteins properly. People with this disorder have inadequate levels of an enzyme that helps break down proteins containing the amino acid leucine. This condition affects an estimated 1 in 50,000 individuals worldwide.

Presentation

Infants with this disorder appear normal at birth but usually develop signs and symptoms during the first year of life or in early childhood. The characteristic features of this condition, which can range from mild to life-threatening, include feeding difficulties, recurrent episodes of vomiting and diarrhea, excessive tiredness (lethargy), and weak muscle tone (hypotonia). If untreated, this disorder can lead to delayed development, seizures, and coma. Early detection and lifelong management (following a low-protein diet and using appropriate supplements) may prevent many of these complications. In some cases, people with gene mutations that cause 3-methylcrotonyl-CoA carboxylase deficiency never experience any signs or symptoms of the disorder.

The characteristic features of this condition are similar to those of Reye syndrome, a severe disorder that develops in children while they appear to be recovering from viral infections such as chicken pox or flu. Most cases of Reye syndrome are associated with the use of aspirin during these viral infections.

Genetics

The MCCC1 and MCCC2 genes make protein subunits that come together to form an enzyme called 3-methylcrotonyl-CoA carboxylase. This enzyme plays an essential role in breaking down proteins from the diet. Specifically, the enzyme is responsible for the fourth step in processing leucine. If a mutation in the MCCC1 or MCCC2 gene reduces or eliminates the activity of 3-methylcrotonyl-CoA carboxylase, the body is unable to process leucine properly. As a result, toxic byproducts of leucine processing build up to harmful levels, damaging the brain and nervous system. This condition is inherited in an autosomal recessive pattern.

Screening

It is one of the 29 conditions currently recommended for newborn screening by the American College of Medical Genetics.

References

This article incorporates public domain text from The U.S. National Library of Medicine

External links

• 3-Methylcrotonyl-CoA carboxylase deficiency at NLM Genetics Home Reference
• SaveBabies